<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03565289</url>
  </required_header>
  <id_info>
    <org_study_id>PROPOSe_1</org_study_id>
    <nct_id>NCT03565289</nct_id>
  </id_info>
  <brief_title>PRospective Prostate biOmarker Study</brief_title>
  <acronym>PROPOSe</acronym>
  <official_title>PRospective Prostate biOmarker Study (PROPOSe)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>ProteoMediX AG</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>ProteoMediX AG</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      • Correlation of a glycoprotein panel with prostate biopsy outcome and PCa aggressiveness
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The main objective of this study is to correlate a glycoprotein panel with prostate biopsy
      outcome, i.e. distinguishing PCa from benign prostatic conditions as well as high-grade
      cancer. The quantities of the two protein analytes cathepsin D (CTSD) and thrombospondin 1
      (THBS1) are measured in human serum samples. In combination with percent free PSA (%fPSA),
      the results are correlated with prostate biopsy outcome. The potential future benefit of
      using this glycoprotein panel is to validate positive tPSA tests in men with negative digital
      rectal examination (DRE) and enlarged prostates to reduce the need for undergoing a biopsy,
      thereby reducing unnecessary biopsies and potentially predicting high-grade disease.
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">August 14, 2018</start_date>
  <completion_date type="Anticipated">January 31, 2020</completion_date>
  <primary_completion_date type="Actual">December 31, 2019</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Diagnosis of PCA</measure>
    <time_frame>6 months</time_frame>
    <description>Correlation of the glycoprotein panel algorithm with histological diagnosis of PCa</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Aggressiveness of PCA</measure>
    <time_frame>6 months</time_frame>
    <description>Correlation of the glycoprotein panel algorithm with diagnosis of significant (Gleason Score ≥7) PCa</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Diagnosis of PCA</measure>
    <time_frame>12 months</time_frame>
    <description>Correlation of the glycoprotein panel algorithm with histological diagnosis of PCa</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Aggressiveness of PCA</measure>
    <time_frame>12 months</time_frame>
    <description>Correlation of the glycoprotein panel algorithm with diagnosis of significant (Gleason Score ≥7) PCa</description>
  </primary_outcome>
  <other_outcome>
    <measure>Glycoprotein panel algorithm</measure>
    <time_frame>After 12 months</time_frame>
    <description>Refinement of the glycoprotein panel algorithm</description>
  </other_outcome>
  <other_outcome>
    <measure>Additional Biomarkers</measure>
    <time_frame>After 12 months</time_frame>
    <description>Correlation of additional biomarkers (e. g. olfactomedin 4 (OLFM4), intercellular adhesion molecule 1 (ICAM1), hypoxia up-regulated protein 1(HYOU1) and metallopeptidase inhibitor 1 (TIMP1)) with histological diagnosis of PCa</description>
  </other_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">455</enrollment>
  <condition>Indication for Prostate Biopsy Due to Suspected Prostate Cancer</condition>
  <arm_group>
    <arm_group_label>All patients</arm_group_label>
    <description>All</description>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Blood sample collection</intervention_name>
    <description>During a routine blood draw an additional tube of blood will be taken for the study.</description>
    <arm_group_label>All patients</arm_group_label>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Blood samples
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with an indication for prostate biopsy at the participating sites.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male patient between 45 and 80 years old.

          -  tPSA between 2 and 10 ng/ml

          -  Prostate volume &gt;=35 ml

          -  Non-suspicious DRE for prostate cancer

          -  Scheduled for prostate biopsy

          -  Patient must give written informed consent

        Exclusion Criteria:

          -  Patient not undergoing biopsy of the prostate

          -  Prior prostate biopsy within the last 12 months

          -  Transurethral resection of the prostate (TURP) in the last 5 years

          -  Patients with known acute or chronic prostatitis/cystitis or other known prostate
             abnormalities

          -  Patient taking 5-alpha-reductase inhibitor

          -  Any other prior treatment of the prostate (cryoablation, hifu, ire, radiation therapy,
             alcohol instillation, etc.)
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>45 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
  </eligibility>
  <overall_official>
    <last_name>Thomas Steuber, Prof. Dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Martiniklinik am UKE gGmbH</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Ordensklinikum Linz</name>
      <address>
        <city>Linz</city>
        <state>Oberösterreich</state>
        <zip>6020</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medizinische Universität Innsbruck</name>
      <address>
        <city>Innsbruck</city>
        <zip>6020</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rigshospitalet</name>
      <address>
        <city>Copenhagen</city>
        <zip>2200</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Münster</name>
      <address>
        <city>Münster</city>
        <state>NRW</state>
        <zip>48149</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Helios Klinikum Bad Saarow</name>
      <address>
        <city>Bad Saarow</city>
        <zip>15526</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Malteser Krankenhaus Bonn/Rhein-Sieg</name>
      <address>
        <city>Bonn</city>
        <zip>53123</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Städtisches Klinikum Braunschweig gGmbH</name>
      <address>
        <city>Braunschweig</city>
        <zip>38126</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Frankfurt</name>
      <address>
        <city>Frankfurt</city>
        <zip>60590</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Martini Klinik am UKE GmbH</name>
      <address>
        <city>Hamburg</city>
        <zip>20246</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Marien-Hospital Herne</name>
      <address>
        <city>Herne</city>
        <zip>44625</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Daikonie Klinikum Stuttgart</name>
      <address>
        <city>Stuttgart</city>
        <zip>70176</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Austria</country>
    <country>Denmark</country>
    <country>Germany</country>
  </location_countries>
  <verification_date>August 2019</verification_date>
  <study_first_submitted>June 7, 2018</study_first_submitted>
  <study_first_submitted_qc>June 20, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">June 21, 2018</study_first_posted>
  <last_update_submitted>January 6, 2020</last_update_submitted>
  <last_update_submitted_qc>January 6, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">January 7, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

